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Peroxisome Proliferator-Activated Receptor alpha
Induction of Uncoupling Protein 2 Protects Against
Acetaminophen-Induced Liver Toxicity
Andrew D. Patterson,1,2 Yatrik M. Shah,1,3 Tsutomu Matsubara,1 Kristopher W. Krausz,1
and Frank J. Gonzalez1
Acetaminophen (APAP) overdose causes acute liver failure in humans and rodents due in
part to the destruction of mitochondria as a result of increased oxidative stress followed by
hepatocellular necrosis. Activation of the peroxisome proliferator-activated receptor alpha
(PPARa), a member of the nuclear receptor superfamily that controls the expression of
genes encoding peroxisomal and mitochondrial fatty acid b-oxidation enzymes, with the
experimental ligand Wy-14,643 or the clinically used ﬁbrate drug fenoﬁbrate, fully
protects mice from APAP-induced hepatotoxicity. PPARa-humanized mice were also pro-
tected, whereas Ppara-null mice were not, thus indicating that the protection extends to
human PPARa and is PPARa-dependent. This protection is due in part to induction of the
PPARa target gene encoding mitochondrial uncoupling protein 2 (UCP2). Forced overex-
pression of UCP2 protected wildtype mice against APAP-induced hepatotoxicity in the ab-
sence of PPARa activation. Ucp2-null mice, however, were sensitive to APAP-induced
hepatotoxicity despite activation of PPARa with Wy-14,643. Protection against hepatotox-
icity by UCP2-induction through activation of PPARa is associated with decreased APAP-
induced c-jun and c-fos expression, decreased phosphorylation of JNK and c-jun, lower
mitochondrial H2O2 levels, increased mitochondrial glutathione in liver, and decreased
levels of circulating fatty acyl-carnitines. These studies indicate that the PPARa target gene
UCP2 protects against elevated reactive oxygen species generated during drug-induced
hepatotoxicity and suggest that induction of UCP2 may also be a general mechanism for
protection of mitochondria during fatty acid b-oxidation. (HEPATOLOGY 2012;56:281-290)
P
eroxisome proliferator-activated receptor alpha
(PPARa), a member of the nuclear receptor
superfamily, controls the expression of a battery
of genes involved in lipid homeostasis including those
encoding peroxisomal and mitochondrial enzymes that
carry out fatty acid catabolism. PPARa is mainly
expressed in organs that are critical in fatty acid catab-
olism, such as liver, heart, and kidney.1-3 Perhaps the
most critical role of PPARa is to modulate hepatic
fatty acid catabolism. In untreated mice, PPARa con-
trols constitutive expression of mitochondrial fatty acid
b-oxidation enzymes.4 During periods of starvation in
mice PPARa is activated, resulting in induction of
both mitochondrial and peroxisomal fatty acid catabo-
lism.5 Notably, in the course of spontaneous and
ligand-induced activation of fatty acid catabolism
excess H2O2 is produced as a byproduct of induction
of peroxisomal acyl-CoA oxidase. Reactive oxygen spe-
cies (ROS) are also produced during mitochondrial
fatty acid b-oxidation. Although this increase in H2O2
is dealt with in part by catalase, glutathione peroxi-
dase, and manganese superoxide dismutase, the cellular
responses to ROS are saturated upon the massive
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activation of fatty acid catabolism that occurs after
ligand activation of PPARa. Consequently, increased
PPARa activity during accelerated fatty acid catabolism
is associated with increased expression of free-radical
scavengers such as catalase and Cu/Zn dismutase6 and
mitochondrial uncoupling proteins (UCPs) that may
serve to reduce mitochondrial ROS levels.7,8 Both
direct and indirect effects suggest that PPARa may
serve a protective role to combat the deleterious side
effects of fatty acid catabolism, thus preserving, in
particular, mitochondrial function.
Increased ROS levels are frequently associated with
hepatotoxicity produced by overdose of drugs such as
acetaminophen (APAP). APAP, the most common
nonprescription analgesic used for pain relief and anti-
pyresis, is a representative compound that causes liver
toxicity upon overdose and is a signiﬁcant public
health concern due to occasional overdose in children
and adults.9,10 A reactive quinone metabolite, N-ace-
tyl-p-benzoquinone imine (NAPQI), generated by
cytochrome P450-catalyzed oxidation, triggers hepatic
toxicity by covalently binding with nucleophilic mac-
romolecules and/or by elevating ROS leading to apo-
ptosis and cell necrosis.11
Interestingly, a connection between PPARa and
APAP toxicity was established when it was discovered
that pretreatment with cloﬁbrate, a PPARa activator,
protected mice against APAP-induced hepatotoxic-
ity12,13 and that this protection was PPARa-depend-
ent.14 Furthermore, it was recently reported that toxic
doses of APAP inhibit fatty acid b-oxidation and that
these effects were signiﬁcantly reduced in mice lacking
the major enzyme responsible for the bioactivation of
APAP, CYP2E1, due, in part, to enhanced and
persistent activation of PPARa and its target genes.15
Wildtype mice treated with APAP, however, showed
suppressed PPARa activity. Thus, PPARa may func-
tion to protect mitochondria from ROS that occurs
during APAP metabolism and as a natural consequence
during fatty acid catabolism. In the present study the
protective effects of PPARa activation during APAP-
induced hepatotoxicity were further investigated and a
role for the PPARa target gene UCP2 in mediating
these protective effects explored.
Materials and Methods
Animals. Wildtype (C57Bl/6J) and ucp2-null
(B6.129-Ucp2tm1Low1/J) mice were obtained from the
Jackson Laboratories (Bar Harbor, ME). Ppara-null
mice and wildtype counterparts on the 129/Sv back-
ground were described previously.16 The PPARa-
humanized mouse was described previously.17 All ani-
mal experiments were carried out in accordance with
the Institute of Laboratory Animal Resources guide-
lines and approved by the National Cancer Institute
Animal Care and Use Committee.
Acetaminophen Experiments. Groups of 6 to 8-
week-old male mice were fed Wy-14,643 (0.1%) diet
for 24 hours before an intraperitoneal injection of
APAP (400 mg/kg) dissolved in saline. All mice were
euthanized by CO2 asphyxiation 2 hours, 6 hours, or
24 hours after the APAP dose. Livers were harvested
and stored at 80C before analysis. To assess liver
damage, tissue was brieﬂy washed with phosphate-buf-
fered saline (PBS) and ﬁxed in 10% neutral buffered
formalin. Necrosis was scored by hematoxylin and eo-
sin (H&E) staining. APAP-induced liver injury was
determined by measuring aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) catalytic
activities in serum using a commercial AST or ALT
assay kit (Catachem, Bridgeport, CT). Reduced gluta-
thione (GSH) levels in liver were measured by a gluta-
thione assay kit (Sigma-Aldrich, St. Louis, MO) and
liver hydrogen peroxide (H2O2) levels were determined
by use of the Peroxidetect kit (Sigma-Aldrich).
RNA Analysis. Dye-coupled complementary DNAs
(cDNAs) were puriﬁed with a MiniElute PCR puriﬁ-
cation kit (Qiagen) and hybridized to an Agilent 44 K
mouse 60-mer oligo microarray (Agilent Technologies,
Santa Clara, CA). The data were processed and ana-
lyzed by Genespring GX software (Agilent Technolo-
gies). Signiﬁcance was determined as >10-fold to the
wildtype control samples. Speciﬁc messenger RNA
(mRNA) levels were determined by quantitative real-
time polymerase chain reaction (qPCR). RNA was
extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA) and qPCR performed using cDNA generated
from 1 lg of total RNA with SuperScriptII Reverse
Transcriptase (Invitrogen). Primers for qPCR were
designed using the Primer Express software (Applied
Biosystems, Foster City, CA). qPCR reactions were
carried out using the SYBR Green PCRmaster mix
(SuperArray, Frederick, MD) and an ABI Prism
7900HT Sequence Detection System (Applied Biosys-
tems). Quantitation was carried out using the compar-
ative cycle threshold (CT) method and results were
normalized to mouse b-actin.
Generation and Infection of the Adenovirus
Constructs Expressing Recombinant UCP2. Rat
UCP2 adenovirus was obtained from the Gene Trans-
fer Vector Core (University of Iowa).18 For in vivo
infection of recombinant adenoviruses, 6 to 8-week-
old wildtype mice were intravenously injected in the
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tail vein with 1.2  1010 infection units, in a total
volume of 400 lL, of recombinant adenoviruses
expressing UCP2 or with an adenovirus expressing Cre
recombinase used as a control. Two days later, mice
were administered APAP and the mice killed after 6
hours or 24 hours.
Western Blot Analysis. Liver whole cell or mito-
chondrial extracts were prepared and subjected to elec-
trophoresis on sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Membranes were
incubated with antibodies against CYP2E1, total JNK,
p-JNK (Cell Signaling Technologies, Danvers, MA), or
UCP2 (Santa Cruz Biotechnology, Santa Cruz, CA).
JNK kinase assays were performed using the nonra-
dioactive SAPK/JNK kinase assay kit (Cell Signaling
Technologies) according to the manufacturer’s
instructions.
Quantitation of APAP Metabolites and Serum
Palmitoylcarnitine. APAP serum metabolites (APAP,
APAP-NAC, APAP-glucuronide, APAP-CYS) were
monitored as described.19 For serum palmitoylcarni-
tine, deproteinated serum samples from wildtype mice
were analyzed by use of an API2000 triplequadrupole
mass spectrometer (Applied Biosystems). Debrisoquine
was used as internal standard. Samples were injected
into a high-performance liquid chromatography
(HPLC) system (PerkinElmer, Waltham, MA) using a
Luna C18 column (Phenomenex, Torrance, CA; 50 
2.1 mm i.d.). The ﬂow rate through the column at
ambient temperature was 0.3 mL/min with a gradient
(methanol:water:acetonitrile, containing 0.1% formic
acid) from 5:60:35 to 5:5:90 in a 6-minute run. The
column was equilibrated for 1.5 minutes before each
injection. The mass spectrometer was operated in the
turbo ion spray mode with positive ion detection; the
turbo ion spray temperature was maintained at 350C
and a voltage of 4.5 kV was applied to the sprayer nee-
dle. Nitrogen was used as the turbo ion spray and nebu-
lizing gas. Detection and quantiﬁcation were performed
using the multiple reactions monitoring mode, with m/z
400.3/85.0 for palmitoylcarnitine and m/z 176.1/134.2
for debrisoquine. Using Analyst software (Applied Bio-
systems), serum palmitoylcarnitine concentrations were
determined by calculating the ratio between the peak
area of palmitoylcarnitine and the peak area of debriso-
quine and ﬁtting with a calibration curve with a linear
range from 10 nM to 1 lM (r ¼ 0.99).
Statistical Analysis. Statistical analysis was per-
formed using GraphPad Prism (San Diego, CA). Anal-
ysis of variance (ANOVA) with Bonferroni’s multiple
comparison test was used to compare the various
groups. P < 0.05 was considered signiﬁcant.
Results
Wy-14,643 Pretreatment Protects Against APAP-
induced Hepatotoxicity. Treatment of wildtype mice
with APAP for 6 hours results in massive hepatic tox-
icity as revealed by gross morphology of the liver (Fig.
1A), increased ALT and AST enzyme levels (Fig. 1B),
and faint pericentral and periportal H&E staining of
liver parenchyma (Fig. 1C). Pretreatment with Wy-
14,643 for 24 hours before APAP treatment results in
total protection against APAP toxicity; Wy-14,643
treated mice had no evidence of liver damage. At 24
hours post-APAP treatment, Wy-14,643-treated mice
were still protected, as indicated by reduced ALT
enzyme levels and normal liver histology (Supporting
Fig. 1). In contrast, Ppara-null mice exhibited no
Wy-14,643 protection against APAP toxicity (shown
by increased ALT and AST activities), indicating that
the protection was PPARa-dependent (Fig. 2A). To
demonstrate that the effect was not speciﬁc to the
experimental ligand Wy-14,643 and to mouse PPARa,
PPARa-humanized mice (a human PPARa gene intro-
duced in the Ppara-null background) treated with
Fig. 1. Wy-14,643 protects against APAP-induced liver toxicity.
Mice were fed a diet containing 0.1% Wy-14,643 24 hours prior to
treatment with APAP. (A) Representative livers from control, Wy-
14,643-treated, APAP-treated, and Wy-14,643/APAP-treated wildtype
mice. (B) Serum AST and ALT enzyme levels from control, Wy-14,643-
treated, APAP-treated, and Wy-14,643/APAP-treated wildtype mice. (C)
H&E staining of livers from Wy-14,643-treated, APAP-treated, and
Wy-14,643/APAP-treated wildtype mice. ***P < 0.001.
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fenoﬁbrate were also protected (Fig. 2B). However,
mice treated with the anti-Fas antibody Jo-2 to stimu-
late Fas receptor-mediated apoptosis were not pro-
tected from Wy-14,643 pretreatment (Supporting Fig.
2). Pretreatment with Wy-14,643 did not signiﬁcantly
impact APAP metabolism, as demonstrated by serum
proﬁling of APAP and its metabolites (APAP-NAC,
APAP-glucuronide, APAP-CYS) 2 hours after APAP
administration (Supporting Fig. 3).
Wy-14,643 Blocks APAP-induced Hepatic Stress
Response Genes. In order to understand the transcrip-
tional responses associated with toxic doses of APAP-
treatment and potential targets whereby PPARa was
mediating its protective affects, microarray analysis was
carried out on liver mRNA from 6 hours APAP-
treated and Wy-14,643-pretreated/APAP-treated mice.
A total of 53 genes were up-regulated by APAP and
45 genes up-regulated by Wy-14,643 /APAP; 14 genes
were up-regulated by both treatments (greater than 10-
fold). Most interesting was the marked induction and
suppression of c-fos and c-jun expression upon APAP
treatment and Wy-14,643-pretreatment prior to APAP
administration, respectively (Fig. 3A). qPCR analysis
conﬁrmed that c-fos and c-jun mRNAs were robustly
induced by APAP and suppressed by Wy-14,643-pre-
treatment prior to APAP (Fig. 3B). Wy-14,643-pre-
treatment also blocked APAP-induced phosphorylation
of JNK, an important signaling component of APAP-
induced toxicity.20-22 Wildtype mice treated with
APAP for 6 hours exhibited increased p-JNK that was
not found with Wy-14,643-pretreatment, whereas
Ppara-null mice have increased p-JNK following
Wy-14,643-pretreatment (Fig. 3C). To ensure that
p-JNK was associated with increased activity, kinase
assays were performed and increased p-JNK levels were
indeed consistent with elevated p-c-jun levels (Fig. 3C,
bottom panel).
Wy-14,643 Blocks APAP-Induced Oxidative Stres-
s. APAP treatment results in a decrease in hepatic lev-
els of GSH at 2 hours and 6 hours, due in part to the
production of the quinone NAPQI from APAP that is
rapidly neutralized by GSH conjugation by glutathione
S-transferase. This decrease was partially restored by
Wy-14,643-pretreatment. However, the maintenance
of GSH levels was even more pronounced in isolated
mitochondria (Fig. 4A). H2O2 levels are inversely cor-
related with GSH levels and reﬂect increase oxidative
stress. Indeed, Wy-14,643-pretreatment decreased
H2O2 levels elevated by APAP treatment, and this was
most pronounced in isolated mitochondria (Fig. 4B).
APAP toxicity is also associated with increased levels
of long-chain acylcarnitines in serum that are likely
due to mitochondrial damage.15 Metabolomics com-
parison of serum revealed marked differences in serum
metabolites between APAP-treated and Wy-14,643-
pretreatment/APAP as indicated by the scores plot sep-
aration of the two groups (Supporting Fig. 4A). This
difference was driven, among others, by differences in
levels of palmitoylcarnitine that were elevated in
APAP-treated mouse serum and normal in
Wy-14,643-pretreatment/APAP (Supporting Fig. 4B).
Pretreatment with Wy-14,643 prior to APAP adminis-
tration blocks the increase in palmitoylcarnitines, as
indicated by direct quantiﬁcation of palmitoylcarnitine
(Fig. 4C).
At 2 hours post-APAP treatment, both APAP- and
Wy-14,643/APAP-treated mice exhibited extensive
GSH depletion in both the liver and mitochondria
(Fig. 4D).
Role of UCP2 in Wy-14-643 Protection Against
APAP-Induced Hepatotoxicity. Because APAP toxicity
results in elevated mitochondrial oxidative stress and
mitochondrial damage, a role for UCP2 in Wy-14,643
Fig. 2. Wy-14,643 protects against APAP-induced liver toxicity.
Mice were fed a diet containing 0.1% Wy-14,643 24 hours prior to
treatment with APAP. (A) Serum AST and ALT enzyme levels from con-
trol, Wy-14,643-treated, APAP-treated, and Wy-14,643/APAP-treated
Ppara-null mice. (B) Serum AST and ALT enzyme levels from control,
fenoﬁbrate-treated, APAP-treated, and fenoﬁbrate/APAP treated
hPPARaPAC mice. ***P < 0.001; ns, not signiﬁcant.
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protection against APAP-induced hepatic damage was
investigated. UCPs are located in the mitochondrial
inner membrane and are associated with decreased he-
patic ROS.23,24 Wy-14,643 treatment induced UCP2
mRNA in the absence and presence of APAP (Fig. 5A,
left panel); similar induction was not observed in
Ppara-null mice. Protein levels of UCP2 were also
measured in mitochondrial extracts from control and
mice treated with Wy-14,643 for 24 hours (Support-
ing Fig. 5). To determine whether UCP2 has a role in
Wy-14,643 protection against APAP hepatotoxicity,
Ucp2-null mice were subjected to Wy-14,643 and
APAP treatment. Mice lacking expression of UCP2
were not protected against APAP-induced toxicity fol-
lowing Wy-14,643, as revealed by serum ALT and
AST enzyme levels (Fig. 5B) and liver histology (Fig.
5C). The Ucp2-null mice were still responsive to Wy-
14,643, as indicated by induction of the PPARa target
genes Mcad, Cpt1, and Pdk4 (Fig. 6A), indicating that
the loss of the protective effects of Wy-14,643 in this
model is due to the lack of UCP2 and not PPARa
itself or other PPARa target genes. Wy-14,643 admin-
istration to Ucp2-null mice also did not restore mito-
chondrial GSH loss upon APAP treatment (Fig. 6B)
nor fully suppressed the increase in p-JNK (Fig. 6C).
These results suggest that the PPARa target gene
UCP2 may be responsible for the protective effect of
PPARa activators against APAP-induced toxicity.
Ucp2-null mice could have subtle changes that
render them resistant to the Wy-14,643 protection
that are unrelated to UCP2. In order to further estab-
lish a role for UCP2 in Wy-14,643-induced protection
against APAP hepatotoxicity, forced expression of the
protein in livers of wildtype mice was carried out.
Recombinant adenoviruses expressing UCP2 (Ad-
Ucp2) were constructed and infused into the mouse
Fig. 3. Changes in gene expression proﬁles,
c-jun and c-fos mRNA levels, and p-JNK asso-
ciated with Wy-14,643 protection against
APAP-induced liver toxicity. (A) Microarray anal-
ysis Venn diagram and table of top hits (APAP-
speciﬁc induction) comparing APAP and Wy-
14,643/APAP-treated wildtype mice. (B) Analy-
sis of c-jun and c-fos mRNAs by qPCR in livers
from control, Wy-14,643-treated, APAP-treated,
and Wy-14,643/APAP-treated wildtype mice.
(C) Levels of p-JNK, JNK, and p-c-jun proteins
in livers from control, Wy-14,643-treated,
APAP-treated, and Wy-14,643/APAP-treated
wildtype mice. ***P < 0.001.
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livers prior to administration of APAP; UCP2 protein
was robustly expressed in the livers of wildtype mice
(Fig. 7, bottom right panel). Mice receiving the Ad-
Ucp2 were protected against APAP-induced liver toxic-
ity as revealed by H&E staining showing protection
against liver necrosis (Fig. 7), lower serum AST and
ALT enzyme activities (Fig. 8A), increased mitochon-
drial GSH (Fig. 8B), and lower p-JNK levels (Fig.
8C). This protection by Ad-Ucp2 was evident at 24
hours post-APAP treatment as indicated by reduced lev-
els of ALT enzyme (Fig. 8D). No protection was found
when the control adenovirus expressing Cre recombinase
was used and adenovirus itself did not appear to inﬂu-
ence CYP2E1 expression (Supporting Fig. 6). ALTactiv-
ity values for Ad-Cre/APAP-treated mice ranged from
1.8 to 8.0 U/mL, whereas values from Ad-Ucp2/APAP-
treated mice ranged from 0.06 to 0.7 U/mL. Even the
highest Ad-Ucp2/APAP ALT activity value was still 2.6
times lower than the lowest Ad-Cre/APAP value. These
data suggest that UCP2 can protect against APAP-
induced hepatotoxicity and that it is a critical target gene
responsible for PPARa-mediated protection during
APAP-induced hepatotoxicity.
Discussion
The present study demonstrates a novel, protective
role for PPARa during APAP-induced hepatotoxicity
and sheds mechanistic insight into the importance of
UCP2 in mediating these protective effects. When the
experimental agonist Wy-14,643 was administered
prior to a toxic dose of APAP, wildtype mice were
completely protected against hepatotoxicity, as revealed
by gross liver morphology, H&E-stained liver sections
showing no signiﬁcant liver damage, and low serum
AST and ALT enzyme levels. In addition, livers from
mice pretreated with Wy-14,643 prior to APAP had
decreased oxidative stress, as revealed by lower H2O2
levels and higher GSH levels compared with livers
from mice only treated with a toxic dose of APAP at 6
Fig. 4. Changes in oxidative stress markers and acycarnitines associated with Wy-14,643 protection against APAP-induced liver toxicity. (A)
Levels of total and mitochondria GSH in livers from control, Wy-14,643-treated, APAP-treated, and Wy-14,643/APAP-treated wildtype mice. (B)
Levels of total and mitochondrial H2O2 in livers from control, Wy-14,643-treated, APAP-treated, and Wy-14,643/APAP-treated wildtype mice. (C)
Levels of serum palmitoylcarnitine from control, Wy-14,643-treated, APAP-treated, and Wy-14,643/APAP-treated wildtype mice. (D) Total (left
panel) and mitochondrial (right panel) GSH levels were measured in livers from control, APAP-treated, and Wy-14,643/APAP-treated (2 hours af-
ter APAP treatment). *P < 0.05, **P < 0.01; ns, not signiﬁcant.
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hours. Interestingly, Wy-14,643-treated mice exhibited
a rapid reduction of GSH levels at 2 hours post-APAP
treatment. In fact, these results are in strong agreement
with a previous report demonstrating that mice lacking
CYP2E1 were protected from APAP-induced hepato-
toxicity due in part to activation of PPARa.15 Evi-
dence for decreased oxidative stress was also revealed
by reduced induction of c-jun and c-fos and lower
p-JNK levels upon Wy-14,643 pretreatment. This
effect was speciﬁc to APAP-induced hepatotoxicity and
JNK pathway attenuation, as Jo-2 treatment that stim-
ulates the Fas death pathway was unaffected by pre-
treatment with Wy-14,643. This observation is consist-
ent with a previous report demonstrating that
attenuating JNK signaling did not protect from Fas-
mediated cell death.20 In general, it is the enhanced
Fig. 5. Role of UCP2 in Wy-
14,643 protection against APAP-
induced liver toxicity using Ucp2-
null mice. (A) qPCR analysis of
UCP2 mRNA in livers from control,
Wy-14,643-treated, APAP-treated,
and Wy-14,643/APAP treated wild-
type mice. (B) Serum ALT and AST
enzyme levels from control, Wy-
14,643-treated, APAP-treated, and
Wy-14,643/APAP-treated Ucp2-null
mice. (C) H&E staining of livers
from Wy-14,643-treated, APAP-
treated, and Wy-14,643/APAP-
treated Ucp2-null mice. **P <
0.01, ***P < 0.001; ns, not
signiﬁcant.
Fig. 6. Role of UCP2 in Wy-14,643 protection
against APAP-induced liver toxicity using Ucp2-
null mice. (A) qPCR analysis of MCAD, CPT1,
and PDK4 mRNA in livers from control, Wy-
14,643-treated, APAP-treated, and Wy-14,643/
APAP-treated Ucp2-null mice. (B) Levels of mito-
chondrial GSH control, Wy-14,643-treated, APAP-
treated, and Wy-14,643/APAP-treated Ucp2-null
mice. (C) Levels of p-JNK, JNK, and p-c-jun pro-
teins in livers from control, Wy-14,643-treated,
APAP-treated, and Wy-14,643/APAP-treated
Ucp2-null mice. *P< 0.05, **P< 0.01.
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and persistent PPARa activation prior to APAP treat-
ment that is important for mediating these effects.
However, studies examining the role of PPARa activa-
tion post-APAP treatment should be conducted to
determine if this pathway holds any promises for ther-
apeutic intervention.
Previous studies revealed that acylcarnitines were ele-
vated early after APAP treatment and that their eleva-
tion was indicative of mitochondrial damage and dys-
function.15,19 In the present study these observations
were conﬁrmed, as palmitoylcarnitine was elevated by
toxic doses of APAP and maintained at normal levels
(compared with untreated controls) by Wy-14,643 pre-
treatment. The enhanced toxicity in the Ppara-null
mice revealed that the protective response to Wy-
14,643 was PPARa-dependent. Protection of APAP
toxicity by Wy-14,643 also extended to human
PPARa, as indicated by similar protection from APAP-
induced hepatotoxicity in PPARa-humanized mice
receiving the PPARa activator fenoﬁbrate.
PPARa activates a large number of target genes pri-
marily associated with fatty acid transport and catabo-
lism. Thus, it was important to determine which
among these target genes afforded protection. Earlier
studies revealed that among the earliest events associ-
ated with APAP toxicity was elevated oxidative stress
as a result of oxidation of APAP to the quinone
metabolite NAPQI by cytochromes P450, notably by
Fig. 7. Role of UCP2 in Wy-14,643 protec-
tion against APAP-induced liver toxicity using
forced expression of UCP2 in livers of wildtype
mice. H&E staining of livers from wildtype
mice administered Ad-Ucp2 and Ad-Cre prior
to APAP treatment. Western blot of UCP2 pro-
tein in Ad-Ucp2 and Ad-Cre treated mice.
Uptake of virus was monitored by PCR of Cre
recombinase cDNA.
Fig. 8. Role of UCP2 in Wy-
14,643 protection against APAP-
induced liver toxicity using forced
expression of UCP2 in livers of
wildtype mice. (A) Effect of Ad-
Ucp2 and Ad-Cre prior to APAP
treatment on serum ALT and AST
enzyme levels. (B) Effect of Ad-
Ucp2 and Ad-Cre prior to APAP
treatment on total mitochondrial
GSH levels in livers of wildtype
mice. (C) Effect of Ad-Ucp2 and
Ad-Cre prior to APAP treatment on
JNK and p-JNK protein levels in liv-
ers of wildtype mice. (D) ALT
enzyme levels in APAP and Ad-
Ucp2 treated mice after 24 hours
APAP treatment. *P < 0.05, **P
< 0.01.
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CYP2E1,11,25 and dramatic reduction of cellular anti-
oxidants including GSH. This is likely followed by mi-
tochondrial damage leading to cell death and these
effects may be partially mediated by reduced PPARa
activity in the presence of high doses of APAP.15,19
The ﬁndings of decreased oxidative stress with Wy-
14,643 suggest that a target gene that inﬂuences liver
ROS and/or preserves mitochondrial fatty acid b-oxi-
dation might be a PPARa-dependent candidate re-
sponsible for the protective effects from APAP-induced
hepatotoxicity.
UCPs are a small family of transporters present in
the inner mitochondria membrane that have been
implicated in the protection against ROS generation in
macrophages. Many studies have revealed that UCPs
regulate mitochondrial ROS26 and, as in the case of
UCP2, can be activated by increased levels of fatty
acids27 such as arachidonate. Furthermore, UCP2 has
been reported to be important for promoting fatty
acid b-oxidation,28 which under conditions of APAP-
induced inhibition of fatty acid catabolism makes it a
likely target for mediating these protective effects.
UCP2 up-regulation in liver is also found in patho-
logic conditions such as steatosis and obesity, where
increased or perturbed fatty acid oxidation is
observed.27,29 High UCP2 expression is also found in
certain tumors where it is thought that the tumor cells
utilize the GSH preserving qualities of UCP2 to pro-
mote growth and reduce ROS levels. UCP2 decreases
ROS in liver through a mechanism that is not com-
pletely understood,23,24 yet the recent report of its
crystal structure is an important step in understanding
the function of UCP2.30 UCP2 may serve a protective
role in mitochondria by reducing ROS levels directly,
lowering mitochondrial membrane potential, transport-
ing fatty acids and fatty acid peroxides, or a combina-
tion of the above. Most important, UCP2 is markedly
induced by PPARa activation in liver, speciﬁcally he-
patocytes7 coincident with the induction of mitochon-
drial and peroxisomal enzymes involved in fatty acid
b-oxidation. Based on these data, UCP2 was viewed as
a potential candidate for a Wy-14,643-induced protein
that could protect from APAP toxicity. Indeed, mice
lacking expression of UCP2 were not protected against
APAP toxicity by Wy-14,643, whereas forced overex-
pression of UCP2 in the liver of wildtype mice also
protected against APAP-induced toxicity in the absence
of Wy-14,643. It is noteworthy, however, that sus-
tained expression of UCP2 may in fact be deleterious,
suggesting that UCP2 expression must be tightly con-
trolled in order to maintain its salubrious qualities.
Furthermore, other UCP family members, namely
UCP3, may also contribute to the protection given the
reduced JNK phosphorylation in Ucp2-null mice
treated with WY-14,643. Moreover, it is likely that the
combined activities of PPARa targets facilitate maxi-
mal protection, and their roles speciﬁcally at the level
of maintaining mitochondrial function warrant further
investigation.
The question arises whether UCP2 plays a role in
protecting the liver against ROS under normal physio-
logical conditions, such as during mitochondrial fatty
acid b-oxidation. In general, Ucp2-null mouse livers
have elevated ROS compared with wildtype mice.31
Thus, UCP2 could serve as a general protector of the
liver and, in particular, of the mitochondria from oxi-
dative stress produced by normal metabolism. Under
conditions of fasting, PPARa is activated by endoge-
nous ligands, resulting in induction of peroxisome and
mitochondrial fatty acid oxidation.32 Indeed, PPARa
activation by starvation results in elevated mitochon-
drial ROS.33 This results in elevated ROS that is neu-
tralized by the coinduced UCP2. In the case of chemi-
cally induced hepatotoxicity that results in massively
elevated and lethal levels of ROS, the protective effect
of UCPs are even more essential.
Another intriguing possibility was demonstrated in a
recent study where the authors reported an intimate
relationship between elevated ROS and UCPs.8 UCP2
(and UCP3) contain reactive cysteines that can be
modiﬁed by GSH. The deglutathionylation/glutathio-
nylation regulates UCP2 and UCP3 activity. In the
presence of elevated ROS, GSH is depleted and the
proteins lose the conjugated glutathione, thereby ren-
dering them active and able to neutralized ROS.
Under the conditions of APAP-induced hepatotoxicity,
elevated ROS levels likely mediate similar activation of
UCP2, however, only following activation by PPARa.
In conclusion, this study adds to our understanding
of how toxic doses of APAP mediate hepatotoxicity
and provides new insight into the importance of
PPARa activation in maintaining proper mitochondrial
function, most likely through UCP2 under normal
and pathologic conditions. Further, this study lends
even greater support for how repression of PPARa
activation can lead to deleterious effects. Using Ucp2-
null mice and mice transiently expressing UCP2 (from
adenovirus), a convincing role for UPC2 in protecting
against APAP-induced hepatotoxicity through preserva-
tion of mitochondrial function was demonstrated. Fur-
ther studies to determine the mechanisms by which
UCP2 facilitates this protection are warranted and will
provide greater understanding by which ROS elevating
hepatoxicants, such as APAP, mediate their effects.
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